Biotage acquires Phynexus in $21.5m deal

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/PeopleImages)
(Image: Getty/PeopleImages)

Related tags: Chromatography, Robotics, Pipette, acquistion, downstream systems

Biotage will add PhyNexus’ platform for higher throughput purification at lab-scale.

Biotage’s acquisition of PhyNexus is expected to strengthen its positions as a separations company in the biomolecule arena.

Per the agreement, Biotage can provide an enabling automation platform to its global customers. The platform is based on dual flow chromatography and uses a patented tip technology for higher throughput purification of biomolecules at lab-scale.

Chromatography and attached platforms to strengthen chromatography units have been a recent addition to facilities across the biopharmaceutical industry as of late.

This testing service is in combination with high throughput pipetting robotics and its new media development program.

The acquisition will cost Biotage $21.5m (€18.8m). The company stated that it will finance the transaction through the issues of 487,337 new shares. The rest will be completed with ‘cash at hand’.

New shares will be issued to the main shareholders of PhyNexus and additional shares may be issued in connection with post-closing price adjustments and earn-out payments. The share and cash transaction is expected to be completed in January 2019.

GE Healthcare recently added a fiber-based purification​ platform to its chromatography portfolio. BIA Separations also expanded its manufacturing site​ to further enable its chromatographic products and increase its capabilities in upstream and downstream processing. 

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more